Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.

Drug Category: Array
Conference Category: Array
Lead Author: Mato A, et al.
Published Date: 01/06/2016
Download Link: /wp-content/uploads/2019/03/EHA%20Integrated%20Analysis%20CLL%20Poster%20FINAL.PDF
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top